FDA Says User Fee Proposal Could Shorten Total Pre-market Review Times

FDA's first crack at an industry user fee reauthorization proposal did not change review goals for 510(k)s, but did suggest some new processes to shorten overall review times for 510(k)s and PMAs alike.